Brief: Eris Lifesciences Launches Generic Semaglutide Under Brand Sundae In India
March 20 (Reuters) - Eris Lifesciences Ltd ERIS.NS: LAUNCHES GENERIC SEMAGLUTIDE UNDER BRAND SUNDAE IN INDIA GENERIC SEMAGLUTIDE LAUNCHES IN INDIA ON MARCH 21, 2026 SUNDAE MULTI-DOSE VIALS PRICED FROM 1,290 RUPEES PER MONTH Source text: ID:nBSE7zs6MW Further company coverage: ERIS.NS ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Eris Lifesciences
See all newsIndia's Eris Lifesciences gains on strong quarterly results
Brief: Eris Lifesciences Sept-Quarter Consol Net Profit 1.84 Billion Rupees
Brief: Eris Lifesciences Says Krishnakumar Vaidyanathan Resigns As Executive Director & COO
Brief: Eris Lifesciences Ltd Says June-Quarter Consol Net Profit 1.42 Billion Rupees
Brief: Eris Lifesciences March-Quarter Consol Net Profit 2.82 Billion Rupees